Evidence map›Paper›PMID 38126364›Full record

ArticleeLife2023

Probing ligand selectivity in pathogens.

Bryan VanSchouwen, Giuseppe Melacini

Open access · goldAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Bryan VanSchouwenDepartment of Chemistry and Chemical Biology, McMaster University, Hamilton, Canada.ORCID 0009-0000-6708-7903
Giuseppe MelaciniDepartment of Chemistry and Chemical Biology, and the Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada.ORCID 0000-0003-1164-2853
McMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Why does protein kinase A respond to purine nucleosides in certain pathogens, but not to the cyclic nucleotides that activate this kinase in most other organisms?

Indexed as

Leishmania donovaniTrypanosoma brucei bruceiCyclic AMP-Dependent Protein KinasesLigandsPhosphotransferasesPurine NucleosidesCyclic AMP-Dependent Protein KinasesLigandsPhosphotransferasesPurine Nucleosidesbiochemistrychemical biologyinfectious diseaseL. donovaniligand selectivitymicrobiologyProtein kinase AT. bruceiT. cruzitrypanosomatid pathogens

Identifiers

PMID38126364
PMCPMC10735216
OpenAlexW4390059564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.